Tramadol and tapentadol hydrochloride: an old and a novel atypical opioid drug. An overview on their present and potential applications

• Autorzy: Giorgi M.
• Języki publikacji: EN

Abstrakty

EN

Acute and chronic pain is a common presenting condition in both animal species and human beings. Classical opioids provide very effective pain relief, although they may be less effective in the treatment of chronic pain due to their limited therapeutic windows and the induced opioid receptor down regulation. Atypical opioids, such as tramadol and tapentadol, have a dual mechanism of action and have been designed to overcome these issues through an opiate-sparing effect. Tramadol activates mu opioid receptors and in addition, inhibits serotonin and noradrenalin reuptake. These actions are the result of the different enantiomers and tend to be reliant on their metabolism. Indeed, the O-desmethyltramadol phase I metabolite, is 200-300 times more potent for mu opioid receptor activation than the parental compound. For these reasons, the drug’s effectiveness can vary among subjects. In veterinary medicine its effectiveness, especially after oral administration, is still uncertain and controversial. Tapentadol is a novel, atypical opioid with a unique mechanism of action. It was launched on the European drug market at the end of 2011. It has been proposed as the first representative of a new pharmacological class of centrally acting analgesics, namely, the mu opioid receptor agonist, noradrenalin reuptake inhibitors. The first human studies describe this molecule as safe and effective (equianalgesic to morphine). The drug has great potential for veterinary use because it exists as a single enantiomer only, it does not require metabolic activation to be effective and adverse effects triggered by the serotonin reuptake inhibition action are negligible. For these reasons, TAP is a promising compound however at this stage, more investigation is required before it can be recommended for regular use in veterinary medicine, the possibility of undesirable effects is yet to be entirely excluded.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2012
• Tom: 68
• Numer: 11
• Opis fizyczny: p.643-646,ref.

Twórcy

autor

Giorgi M.

• Department of Veterinary Clinics, 24h Veterinary Teaching Hospital, University of Pisa, Via Livornese (lato monte) 1, San Piero a Grado, 56101, Pisa, Italy

Bibliografia

• 1.Afilalo M., Etropolski M. S., Kuperwasser B., Kelly K., Okamoto A., Van Hove I., Steup A., Lange B., Rauschkolb C., Haeussler J.: Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo- and active-controlled phase III study. Clin. Drug Invest. 2010, 30, 489-505.
• 2.Ahlbeck K.: Opioids: A two-faced Janus. Curr. Med. Res. Opin. 2011, 27, 439-448.
• 3.Black P. A., Cox S. K., Macek M., Tieber A., Junge R. E.: Pharmacokinetics of tramadol hydrochloride and its metabolite O-desmethyltramadol in peafowl (Pavo cristatus). J. Zoo Wildl. Med. 2010, 41, 671-676.
• 4.Briley M.: Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum. Psychopharmacol. 2004, Suppl 1, S21-25.
• 5.Cox S., Martin-Jimenez T., van Amstel S., Doherty T.: Pharmacokinetics of intravenous and intramuscular tramadol in llamas. J. Vet. Pharmacol. Ther. 2011, 34, 259-264.
• 6.Cox S., Villarino N., Doherty T.: Determination of oral tramadol pharmacokinetics in horses. Res. Vet. Sci. 2010, 89, 236-241.
• 7.Dickenson A. H., Suzuki R.: Opioids in neuropathic pain: clues from animal studies. Eur. J. Pain. 2005, 9, 113-116.
• 8.Emmerich I. U.: New drugs for small animals in 2010. Tierarztl. Prax. Ausg. K. Kleintiere Heimtiere 2011, 39, 429-435.
• 9.Enggaard T. P., Poulsen L., Arendt-Nielsen L., Brøsen K., Ossig J., Sindrup S. H.: The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 2006, 102, 146-150.
• 10.Etropolski M., Kelly K., Okamoto A., Rauschkolb C.: Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv. Ther. 2011, 28, 401-417.
• 11.Friderichs E., Buschmann H.: Opioids: 3.4 Opioids with Clinical Relevance, [in:] Buschmann H., Christoph T., Maul C., Sundermann B. (eds): Analgesics: From Chemistry and Pharmacology to Clinical Application. Wiley-VHC, Weinheim, Germany 2005, pp 171-245.
• 12.Giorgi M., Del Carlo S., Łebkowska-Wieruszewska B., Kowalski C. J., Saccomanni G.: Pharmacokinetics of tramadol and metabolites after injective administrations in dogs. Pol. J. Vet. Sci. 2010, 13, 639-644.
• 13.Giorgi M., Del Carlo S., Saccomanni G., Łebkowska-Wieruszewska B., Kowalski C. J.: Pharmacokinetic and urine profile of tramadol and its major metabolites following oral immediate release capsules administration in dogs. Vet. Res. Commun. 2009b, 33, 875-885.
• 14.Giorgi M., Del Carlo S., Saccomanni G., Łebkowska-Wieruszewska B. Kowalski C. J.: Pharmacokinetics of tramadol and its major metabolites following rectal and intravenous administration in dogs. N Z Vet J. 2009c, 57, 146-152.
• 15.Giorgi M., Del Carlo S., Saccomanni G., Łebkowska-Wieruszewska B., Turini V., Kowalski C.: Biopharmaceutical profile of tramadol in the dog. Vet. Res. Commun. 2009a 33, Suppl 1, S189-192.
• 16.Giorgi M., Saccomanni G., Andreoni V.: Pharmacokinetics of Tramadol after Epidural Administration in Horses. J. Equine Vet. Sci. 2010, 30, 44-46.
• 17.Giorgi M., Saccomanni G., Del Carlo S., Andreoni V.: Pharmacokinetic of tramadol and its major metabolites after intravenous and intramuscular injections in alpacas (Vicugna pacos). J. Camel Pract. Res. 2010, 17, 123-126.
• 18.Giorgi M., Saccomanni G., Lebkowska-Wieruszewska B., Kowalski C.: Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. Vet. J. 2009d, 180, 253-255.
• 19.Giorgi M., Soldani G., Manera C., Ferrarini P., Sgorbini M., Saccomanni G.: Pharmacokinetics of Tramadol and its Metabolites M1, M2 and M5 in Horses Following Intravenous, Immediate Release (Fasted/Fed) and Sustained Release Single Dose Administration. J. Equine Vet. Sci. 2007, 27, 481-488.
• 20.Grond S., Meuser T., Uragg H., Stahlberg H. J., Lehmann K. A.: Serum concentrations of tramadol enantiomers during patient-controlled analgesia. Br. J. Clin. Pharmacol. 1999, 48, 254-257.
• 21.Grond S., Sablotzki A.: Clinical pharmacology of tramadol. Clin. Pharmacokinet. 2004, 43, 879-923.
• 22.Hui-Chen L., Yang Y., Na W., Ming D., Jian-Fang L., Hong-Yuan X.: Pharmacokinetics of the enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in healthy male and female chinese volunteers. Chirality 2004, 16, 112-118.
• 23.Kieffer B. L.: Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. 1999, 20, 19-26.
• 24.Kress H. G.: Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur. J. Pain 2010, 14, 781-783.
• 25.Kukanich B., Papich M. G.: Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. Am. J. Vet. Res. 2011, 72, 256-262.
• 26.Lehmann K. A., Kratzenberg U., Schroeder-Bark B., Horrichs-Haermeyer G.: Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations. Clin. J. Pain 1990, 6, 212-220.
• 27.Meldrum M. L.: Opioids and pain relief: a historical perspective. Meldrum M. L. (ed), IASP Press, Seattle, USA 2003.
• 28.McMillan C. J., Livingston A., Clark C. R., Dowling P. M., Taylor S. M., Duke T., Terlinden R.: Pharmacokinetics of intravenous tramadol in dogs. Can. J. Vet. Res. 2008, 72, 325-331.
• 29.Pypendop B. H., Ilkiw J. E.: Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. J. Vet. Pharmacol. Ther. 2008, 31, 52-59.
• 30.Pypendop B. H., Siao K. T., Ilkiw J. E.: Effects of tramadol hydrochloride on the thermal threshold in cats. Am. J. Vet. Res. 2009, 70, 1465-1470.
• 31.Shilo Y., Britzi M., Eytan B., Lifschitz T., Soback S., Steinman A.: Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. J. Vet. Pharmacol. Ther. 2008, 31, 60-65.
• 32.Sousa A. B. de, Santos A. C., Schramm S. G., Porta V., Górniak S. L., Florio J. C., de Souza Spinosa H.: Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. J. Vet. Pharmacol. Ther. 2008, 31, 45-51.
• 33.Souza M. J., Cox S. K.: Tramadol use in zoologic medicine. Vet. Clin. North Am. Exot. Anim. Pract. 2011, 14, 117-130.
• 34.Souza M. J., Martin-Jimenez T., Jones M. P., Cox S. K.: Pharmacokinetics of oral tramadol in red-tailed hawks (Buteo jamaicensis). J. Vet. Pharmacol. Ther. 2011, 34, 86-88.
• 35.Staiger T. O., Gaster B., Sullivan M. D., Deyo R. A.: Systematic review of antidepressants in the treatment of chronic low back pain. Spine 2003, 28, 2540-2545.
• 36.Stamer U. M., Musshoff F., Kobilay M., Madea B., Hoeft A., Stuber F.: Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. 2007, 82, 41-47.
• 37.Suzuki R., Rygh L. J., Dickenson A. H.: Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol. Sci. 2004, 25, 613-617.
• 38.Terlinden R., Ossig J., Fliegert F., Lange C., Göhler K.: Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 2007, 32, 163-169.
• 39.Tzschentke T. M., De Vry J., Terlinden R., Hennies H. H., Lange C., Strassburger W., Haurand M., Kolb J., Schneider J., Buschmann H., Finkam M., Jahnel U., Friderichs E.: Tapentadol hydrochloride: Analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor. Drugs Future 2006, 31, 1053-1061.
• 40.Tzschentke T. M., Jahnel U., Kögel B., Christoph T., Englberger W., De Vry J., Schiene K., Okamoto A., Upmalis D., Weber H., Lange C., Stegmann J. U., Kleinert R.: Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 2009, 45, 483-496.
• 41.Vettorato E., Zonca A., Isola M., Villa R., Gallo M., Ravasio G., Beccaglia M., Montesissa C., Cagnardi P.: Pharmacokinetics and efficacy of intravenous and extradural tramadol in dogs. Vet. J. 2010, 183, 310-315.
• 42.Wang Y., Feng C., Wu Z., Wu A., Yue Y.: Activity of the descending noradrenergic pathway after surgery in rats. Acta Anaesthesiol. Scand. 2008, 52, 1336-1341.
• 43.Wilhorn S., Kraus C.: In patients experiencing acute pain, how does the efficacy and gastrointestinal tolerability of tapentadol compare with oxycodone? Evidence-Based Pract. 2011, 14, 14.

Uwagi

Rekord w opracowaniu